Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Warned by Nasdaq for Non-compliance with Listing Rule

NEW YORK (GenomeWeb) — Response Genetics has been warned by Nasdaq that it is not in compliance with a rule to remain listing on the Nasdaq Capital Market, the company recently disclosed in a document filed with the US Securities and Exchange Commission.

Nasdaq sent a letter to the firm in late November saying it does not meet a listing requirement calling for a minimum of $2.5 million stockholders' equity. For the third quarter ended Sept. 30, Response Genetics had shareholders' equity of about $2.0 million, according to the firm's Form 10-Q. 

The company has 45 days to submit a plan to regain compliance with the Nasdaq listing rule, and said in the SEC document that it is working on such a plan. Its deadline for submitting the plan is Jan. 8, 2015.

 

 

 

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.